Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment

INTRODUCTION: NSCLC harboring activating mutations of EGFR is highly sensitive to first-line EGFR-tyrosine kinase inhibitors (TKIs), but drug resistance depending on the EGFR mutation p.T790M will occur in about 50-60% of patients. Detailed information on the amount of p.T790M plasmatic level associ...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Del Re, Marzia, Bordi, Paola, Petrini, Iacopo, Rofi, Eleonora, Mazzoni, Francesca, Belluomini, Lorenzo, Vasile, Enrico, Restante, Giuliana, Di Costanzo, Francesco, Falcone, Alfredo, Frassoldati, Antonio, van Schaik, Ron H.N., Steendam, Christi M.J., Chella, Antonio, Tiseo, Marcello, Morganti, Riccardo, Danesi, Romano
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2017
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5689667/
https://ncbi.nlm.nih.gov/pubmed/29156777
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.20947
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados